1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Orphan Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Oncology
1.2.3 Pulmonary
1.2.4 Neurology
1.2.5 Hematology
1.2.6 Endocrinology
1.2.7 Cardio-vascular
1.2.8 Metabolic Disorders
1.2.9 Others
1.3 Market by End Users
1.3.1 Global Orphan Drugs Market Share by End Users: 2017 VS 2021 VS 2028
1.3.2 Baby and Child
1.3.3 Teenager
1.3.4 Adult
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Orphan Drugs Market Perspective (2017-2028)
2.2 Orphan Drugs Growth Trends by Region
2.2.1 Orphan Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Orphan Drugs Historic Market Size by Region (2017-2022)
2.2.3 Orphan Drugs Forecasted Market Size by Region (2023-2028)
2.3 Orphan Drugs Market Dynamics
2.3.1 Orphan Drugs Industry Trends
2.3.2 Orphan Drugs Market Drivers
2.3.3 Orphan Drugs Market Challenges
2.3.4 Orphan Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Orphan Drugs Players by Revenue
3.1.1 Global Top Orphan Drugs Players by Revenue (2017-2022)
3.1.2 Global Orphan Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Orphan Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Orphan Drugs Revenue
3.4 Global Orphan Drugs Market Concentration Ratio
3.4.1 Global Orphan Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Orphan Drugs Revenue in 2021
3.5 Orphan Drugs Key Players Head office and Area Served
3.6 Key Players Orphan Drugs Product Solution and Service
3.7 Date of Enter into Orphan Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Orphan Drugs Breakdown Data by Type
4.1 Global Orphan Drugs Historic Market Size by Type (2017-2022)
4.2 Global Orphan Drugs Forecasted Market Size by Type (2023-2028)
5 Orphan Drugs Breakdown Data by End Users
5.1 Global Orphan Drugs Historic Market Size by End Users (2017-2022)
5.2 Global Orphan Drugs Forecasted Market Size by End Users (2023-2028)
6 North America
6.1 North America Orphan Drugs Market Size (2017-2028)
6.2 North America Orphan Drugs Market Size by Country (2017-2022)
6.3 North America Orphan Drugs Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Orphan Drugs Market Size (2017-2028)
7.2 Europe Orphan Drugs Market Size by Country (2017-2022)
7.3 Europe Orphan Drugs Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Orphan Drugs Market Size (2017-2028)
8.2 Asia-Pacific Orphan Drugs Market Size by Country (2017-2022)
8.3 Asia-Pacific Orphan Drugs Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Orphan Drugs Market Size (2017-2028)
9.2 Latin America Orphan Drugs Market Size by Country (2017-2022)
9.3 Latin America Orphan Drugs Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Orphan Drugs Market Size (2017-2028)
10.2 Middle East & Africa Orphan Drugs Market Size by Country (2017-2022)
10.3 Middle East & Africa Orphan Drugs Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Detail
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Orphan Drugs Introduction
11.1.4 Bristol-Myers Squibb Revenue in Orphan Drugs Business (2017-2022)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Orphan Drugs Introduction
11.2.4 Roche Revenue in Orphan Drugs Business (2017-2022)
11.2.5 Roche Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Orphan Drugs Introduction
11.3.4 Novartis Revenue in Orphan Drugs Business (2017-2022)
11.3.5 Novartis Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Detail
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Orphan Drugs Introduction
11.4.4 Johnson & Johnson Revenue in Orphan Drugs Business (2017-2022)
11.4.5 Johnson & Johnson Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Orphan Drugs Introduction
11.5.4 Pfizer Revenue in Orphan Drugs Business (2017-2022)
11.5.5 Pfizer Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Orphan Drugs Introduction
11.6.4 Amgen Revenue in Orphan Drugs Business (2017-2022)
11.6.5 Amgen Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Detail
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Orphan Drugs Introduction
11.7.4 Sanofi Revenue in Orphan Drugs Business (2017-2022)
11.7.5 Sanofi Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Detail
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Orphan Drugs Introduction
11.8.4 AstraZeneca Revenue in Orphan Drugs Business (2017-2022)
11.8.5 AstraZeneca Recent Development
11.9 Takeda
11.9.1 Takeda Company Detail
11.9.2 Takeda Business Overview
11.9.3 Takeda Orphan Drugs Introduction
11.9.4 Takeda Revenue in Orphan Drugs Business (2017-2022)
11.9.5 Takeda Recent Development
11.10 Vertex Pharmaceuticals
11.10.1 Vertex Pharmaceuticals Company Detail
11.10.2 Vertex Pharmaceuticals Business Overview
11.10.3 Vertex Pharmaceuticals Orphan Drugs Introduction
11.10.4 Vertex Pharmaceuticals Revenue in Orphan Drugs Business (2017-2022)
11.10.5 Vertex Pharmaceuticals Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Detail
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Orphan Drugs Introduction
11.11.4 AbbVie Revenue in Orphan Drugs Business (2017-2022)
11.11.5 AbbVie Recent Development
11.12 Biogen
11.12.1 Biogen Company Detail
11.12.2 Biogen Business Overview
11.12.3 Biogen Orphan Drugs Introduction
11.12.4 Biogen Revenue in Orphan Drugs Business (2017-2022)
11.12.5 Biogen Recent Development
11.13 Eli Lilly
11.13.1 Eli Lilly Company Detail
11.13.2 Eli Lilly Business Overview
11.13.3 Eli Lilly Orphan Drugs Introduction
11.13.4 Eli Lilly Revenue in Orphan Drugs Business (2017-2022)
11.13.5 Eli Lilly Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Orphan Drugs Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Oncology
Table 3. Key Players of Pulmonary
Table 4. Key Players of Neurology
Table 5. Key Players of Hematology
Table 6. Key Players of Endocrinology
Table 7. Key Players of Cardio-vascular
Table 8. Key Players of Metabolic Disorders
Table 9. Key Players of Others
Table 10. Global Orphan Drugs Market Size Growth by End Users (US$ Million): 2017 VS 2021 VS 2028
Table 11. Global Orphan Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 12. Global Orphan Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 13. Global Orphan Drugs Market Share by Region (2017-2022)
Table 14. Global Orphan Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 15. Global Orphan Drugs Market Share by Region (2023-2028)
Table 16. Orphan Drugs Market Trends
Table 17. Orphan Drugs Market Drivers
Table 18. Orphan Drugs Market Challenges
Table 19. Orphan Drugs Market Restraints
Table 20. Global Orphan Drugs Revenue by Players (2017-2022) & (US$ Million)
Table 21. Global Orphan Drugs Market Share by Players (2017-2022)
Table 22. Global Top Orphan Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orphan Drugs as of 2021)
Table 23. Ranking of Global Top Orphan Drugs Companies by Revenue (US$ Million) in 2021
Table 24. Global 5 Largest Players Market Share by Orphan Drugs Revenue (CR5 and HHI) & (2017-2022)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Orphan Drugs Product Solution and Service
Table 27. Date of Enter into Orphan Drugs Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Orphan Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 30. Global Orphan Drugs Revenue Market Share by Type (2017-2022)
Table 31. Global Orphan Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 32. Global Orphan Drugs Revenue Market Share by Type (2023-2028)
Table 33. Global Orphan Drugs Market Size by End Users (2017-2022) & (US$ Million)
Table 34. Global Orphan Drugs Revenue Market Share by End Users (2017-2022)
Table 35. Global Orphan Drugs Forecasted Market Size by End Users (2023-2028) & (US$ Million)
Table 36. Global Orphan Drugs Revenue Market Share by End Users (2023-2028)
Table 37. North America Orphan Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 38. North America Orphan Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 39. Europe Orphan Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 40. Europe Orphan Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 41. Asia-Pacific Orphan Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 42. Asia-Pacific Orphan Drugs Market Size by Region (2023-2028) & (US$ Million)
Table 43. Latin America Orphan Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 44. Latin America Orphan Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 45. Middle East & Africa Orphan Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 46. Middle East & Africa Orphan Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 47. Bristol-Myers Squibb Company Detail
Table 48. Bristol-Myers Squibb Business Overview
Table 49. Bristol-Myers Squibb Orphan Drugs Product
Table 50. Bristol-Myers Squibb Revenue in Orphan Drugs Business (2017-2022) & (US$ Million)
Table 51. Bristol-Myers Squibb Recent Development
Table 52. Roche Company Detail
Table 53. Roche Business Overview
Table 54. Roche Orphan Drugs Product
Table 55. Roche Revenue in Orphan Drugs Business (2017-2022) & (US$ Million)
Table 56. Roche Recent Development
Table 57. Novartis Company Detail
Table 58. Novartis Business Overview
Table 59. Novartis Orphan Drugs Product
Table 60. Novartis Revenue in Orphan Drugs Business (2017-2022) & (US$ Million)
Table 61. Novartis Recent Development
Table 62. Johnson & Johnson Company Detail
Table 63. Johnson & Johnson Business Overview
Table 64. Johnson & Johnson Orphan Drugs Product
Table 65. Johnson & Johnson Revenue in Orphan Drugs Business (2017-2022) & (US$ Million)
Table 66. Johnson & Johnson Recent Development
Table 67. Pfizer Company Detail
Table 68. Pfizer Business Overview
Table 69. Pfizer Orphan Drugs Product
Table 70. Pfizer Revenue in Orphan Drugs Business (2017-2022) & (US$ Million)
Table 71. Pfizer Recent Development
Table 72. Amgen Company Detail
Table 73. Amgen Business Overview
Table 74. Amgen Orphan Drugs Product
Table 75. Amgen Revenue in Orphan Drugs Business (2017-2022) & (US$ Million)
Table 76. Amgen Recent Development
Table 77. Sanofi Company Detail
Table 78. Sanofi Business Overview
Table 79. Sanofi Orphan Drugs Product
Table 80. Sanofi Revenue in Orphan Drugs Business (2017-2022) & (US$ Million)
Table 81. Sanofi Recent Development
Table 82. AstraZeneca Company Detail
Table 83. AstraZeneca Business Overview
Table 84. AstraZeneca Orphan Drugs Product
Table 85. AstraZeneca Revenue in Orphan Drugs Business (2017-2022) & (US$ Million)
Table 86. AstraZeneca Recent Development
Table 87. Takeda Company Detail
Table 88. Takeda Business Overview
Table 89. Takeda Orphan Drugs Product
Table 90. Takeda Revenue in Orphan Drugs Business (2017-2022) & (US$ Million)
Table 91. Takeda Recent Development
Table 92. Vertex Pharmaceuticals Company Detail
Table 93. Vertex Pharmaceuticals Business Overview
Table 94. Vertex Pharmaceuticals Orphan Drugs Product
Table 95. Vertex Pharmaceuticals Revenue in Orphan Drugs Business (2017-2022) & (US$ Million)
Table 96. Vertex Pharmaceuticals Recent Development
Table 97. AbbVie Company Detail
Table 98. AbbVie Business Overview
Table 99. AbbVie Orphan DrugsProduct
Table 100. AbbVie Revenue in Orphan Drugs Business (2017-2022) & (US$ Million)
Table 101. AbbVie Recent Development
Table 102. Biogen Company Detail
Table 103. Biogen Business Overview
Table 104. Biogen Orphan DrugsProduct
Table 105. Biogen Revenue in Orphan Drugs Business (2017-2022) & (US$ Million)
Table 106. Biogen Recent Development
Table 107. Eli Lilly Company Detail
Table 108. Eli Lilly Business Overview
Table 109. Eli Lilly Orphan DrugsProduct
Table 110. Eli Lilly Revenue in Orphan Drugs Business (2017-2022) & (US$ Million)
Table 111. Eli Lilly Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Orphan Drugs Market Share by Type: 2021 VS 2028
Figure 2. Oncology Features
Figure 3. Pulmonary Features
Figure 4. Neurology Features
Figure 5. Hematology Features
Figure 6. Endocrinology Features
Figure 7. Cardio-vascular Features
Figure 8. Metabolic Disorders Features
Figure 9. Others Features
Figure 10. Global Orphan Drugs Market Share by End Users in 2021 & 2028
Figure 11. Baby and Child Case Studies
Figure 12. Teenager Case Studies
Figure 13. Adult Case Studies
Figure 14. Other Case Studies
Figure 15. Orphan Drugs Report Years Considered
Figure 16. Global Orphan Drugs Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 17. Global Orphan Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 18. Global Orphan Drugs Market Share by Region: 2021 VS 2028
Figure 19. Global Orphan Drugs Market Share by Players in 2021
Figure 20. Global Top Orphan Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orphan Drugs as of 2021)
Figure 21. The Top 10 and 5 Players Market Share by Orphan Drugs Revenue in 2021
Figure 22. North America Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. North America Orphan Drugs Market Share by Country (2017-2028)
Figure 24. United States Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Canada Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Europe Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Europe Orphan Drugs Market Share by Country (2017-2028)
Figure 28. Germany Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. France Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. U.K. Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Italy Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Russia Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Nordic Countries Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Asia-Pacific Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Asia-Pacific Orphan Drugs Market Share by Region (2017-2028)
Figure 36. China Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Japan Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. South Korea Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Southeast Asia Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. India Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Australia Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Latin America Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Latin America Orphan Drugs Market Share by Country (2017-2028)
Figure 44. Mexico Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Brazil Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Middle East & Africa Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Middle East & Africa Orphan Drugs Market Share by Country (2017-2028)
Figure 48. Turkey Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Saudi Arabia Orphan Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 50. Bristol-Myers Squibb Revenue Growth Rate in Orphan Drugs Business (2017-2022)
Figure 51. Roche Revenue Growth Rate in Orphan Drugs Business (2017-2022)
Figure 52. Novartis Revenue Growth Rate in Orphan Drugs Business (2017-2022)
Figure 53. Johnson & Johnson Revenue Growth Rate in Orphan Drugs Business (2017-2022)
Figure 54. Pfizer Revenue Growth Rate in Orphan Drugs Business (2017-2022)
Figure 55. Amgen Revenue Growth Rate in Orphan Drugs Business (2017-2022)
Figure 56. Sanofi Revenue Growth Rate in Orphan Drugs Business (2017-2022)
Figure 57. AstraZeneca Revenue Growth Rate in Orphan Drugs Business (2017-2022)
Figure 58. Takeda Revenue Growth Rate in Orphan Drugs Business (2017-2022)
Figure 59. Vertex Pharmaceuticals Revenue Growth Rate in Orphan Drugs Business (2017-2022)
Figure 60. AbbVie Revenue Growth Rate in Orphan Drugs Business (2017-2022)
Figure 61. Biogen Revenue Growth Rate in Orphan Drugs Business (2017-2022)
Figure 62. Eli Lilly Revenue Growth Rate in Orphan Drugs Business (2017-2022)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
